Grace Therapeutics Current Cash

Grace Therapeutics (GRCE) currently reports a current cash of $14M as of June 2026. That compares with $20M in the prior-year period — down 31.2% year over year. Use the charts on this page to explore Grace Therapeutics's current cash history and peer comparisons.

Grace Therapeutics's current cash decreased from $20M to $14M — a 31.2% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Grace Therapeutics reported $14M in current cash as of June 2026. That compares with $20M in the prior-year period — down 31.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $14M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Grace Therapeutics, and consider following GRCE for alerts when major investors trade the stock.

Grace Therapeutics is classified in the Healthcare sector. On current cash, it currently shows $14M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GRCE with unrelated industries.